NO20032938L - Kvatern¶re ammoniumforbindelser samt deres anvendelse som anti-muskariniskemidler - Google Patents

Kvatern¶re ammoniumforbindelser samt deres anvendelse som anti-muskariniskemidler

Info

Publication number
NO20032938L
NO20032938L NO20032938A NO20032938A NO20032938L NO 20032938 L NO20032938 L NO 20032938L NO 20032938 A NO20032938 A NO 20032938A NO 20032938 A NO20032938 A NO 20032938A NO 20032938 L NO20032938 L NO 20032938L
Authority
NO
Norway
Prior art keywords
well
quaternary ammonium
ammonium compounds
muscarinic agents
trifluoromethyl
Prior art date
Application number
NO20032938A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032938D0 (no
Inventor
Ivan Richards
Sergey G Wolfson
Sue K Cammarata
Patrick J Lennon
Craig D Wegner
Michael Hawley
Mark P Warchol
Mark J Kontny
Walter Morozowich
Karen P Kolbasa
Malcolm W Moon
Dominique Bonafoux
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO20032938D0 publication Critical patent/NO20032938D0/no
Publication of NO20032938L publication Critical patent/NO20032938L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/66Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with quaternised amino groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20032938A 2001-10-26 2003-06-26 Kvatern¶re ammoniumforbindelser samt deres anvendelse som anti-muskariniskemidler NO20032938L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34893001P 2001-10-26 2001-10-26
US36197902P 2002-03-06 2002-03-06
US39152102P 2002-06-25 2002-06-25
PCT/US2002/034529 WO2003035599A1 (en) 2001-10-26 2002-10-25 Quarternary ammonium compounds and their use as antimuscarinic agents

Publications (2)

Publication Number Publication Date
NO20032938D0 NO20032938D0 (no) 2003-06-26
NO20032938L true NO20032938L (no) 2003-08-25

Family

ID=27407868

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032938A NO20032938L (no) 2001-10-26 2003-06-26 Kvatern¶re ammoniumforbindelser samt deres anvendelse som anti-muskariniskemidler

Country Status (16)

Country Link
US (2) US6890920B2 (da)
EP (1) EP1461306B1 (da)
JP (1) JP3981357B2 (da)
AT (1) ATE418534T1 (da)
BR (1) BR0206207A (da)
CA (1) CA2464223C (da)
CY (1) CY1109898T1 (da)
DE (1) DE60230546D1 (da)
DK (1) DK1461306T3 (da)
ES (1) ES2315425T3 (da)
MX (1) MXPA04003865A (da)
MY (1) MY130316A (da)
NO (1) NO20032938L (da)
PT (1) PT1461306E (da)
SG (1) SG168451A1 (da)
WO (1) WO2003035599A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US6890920B2 (en) * 2001-10-26 2005-05-10 Pharmacia & Upjohn Company Quaternary ammonium compounds
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
WO2004000280A1 (en) * 2002-04-29 2003-12-31 Shire Laboraties, Inc. Pharmaceutical formulations with improved bioavailability
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
US20040242569A1 (en) * 2003-04-15 2004-12-02 Pfizer Inc. Quatemary ammonium compounds
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
EP1620389A1 (en) * 2003-04-25 2006-02-01 Pharmacia & Upjohn Company LLC Halogen substituted 3,3-diphenylpropylamines (tolterodine) having antimuscarinic activity
JP5610663B2 (ja) 2003-11-04 2014-10-22 スパーナス ファーマシューティカルズ インコーポレイテッド トロスピウムの1日1回剤形
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
KR101154023B1 (ko) * 2003-12-24 2012-06-07 씨아이피엘에이 엘티디. 톨테로딘, 그 조성물 및 용도, 그리고 그 제조방법
WO2005086873A2 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
US20080045602A1 (en) * 2004-12-24 2008-02-21 Casar Renata T Process for Preparation of 3-(2-Hydroxy-5Methylphenyl)-N, N-Disopropyl-3-Phenylpropylamine
US20110135580A1 (en) * 2006-05-24 2011-06-09 Boehringer Ingelheim International Gmbh Novel Medicament Combinations for the Treatment of Respiratory Diseases
EP1908502A1 (en) * 2006-10-02 2008-04-09 Koninklijke Philips Electronics N.V. Interactive modular tile system
US7731604B2 (en) * 2006-10-31 2010-06-08 Taylor Made Golf Company, Inc. Golf club iron head
EP2114972A2 (en) * 2006-12-13 2009-11-11 Gilead Sciences, Inc. Monophosphates as mutual prodrugs of muscarinic receptor antagonists and beta-agonists for the treatment of copd and chronic bronchitis
BRPI0807615A8 (pt) * 2007-02-23 2017-12-05 Theravance Inc Compostos de difenilmetil amônico quaternário úteis como antagonistas de receptor muscarínico
WO2008133900A1 (en) 2007-04-24 2008-11-06 Theravance, Inc. Quaternary ammonium compounds useful as muscarinic receptor antagonists
US20090246146A1 (en) * 2008-01-25 2009-10-01 Botond Banfi Halides in the treatment of pathogenic infection
AR074148A1 (es) * 2008-06-10 2010-12-29 Gilead Sciences Inc Derivados de corticoesteroides beta agonistas fosforilados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades del aparato respiratorio
WO2010010464A2 (en) * 2008-07-21 2010-01-28 Actavis Group Ptc Ehf Fesoterodine substantially free of dehydroxy impurity
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドPfizer Limited 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CN110372571B (zh) 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物
CN110845357B (zh) * 2019-11-22 2022-09-30 华东理工大学 季铵盐型酰肼化合物及由其制备的季铵盐型腙类化合物与应用
CN116033893A (zh) 2020-06-26 2023-04-28 迈兰制药英国有限公司 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE106643C (da)
US2592191A (en) * 1949-09-16 1952-04-08 Sterling Drug Inc Quaternary ammonium salts of nu-(3, 3-diphenylpropyl) pyrrolidine
NL267508A (da) 1960-07-26
NL6717123A (da) * 1966-12-29 1968-07-01
US3505337A (en) * 1967-12-22 1970-04-07 Boehringer Sohn Ingelheim N - hydrocarbyl-substituted noratropinium,haloalkylates and o-acyl derivatives thereof
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
IL91377A (en) * 1988-09-14 1996-09-12 Nippon Shinyaku Co Ltd Derivatives of botinylamine glycolate
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
WO1995010270A1 (en) 1993-10-08 1995-04-20 Sepracor, Inc. Method for treating urinary incontinence using optically pure s-terodiline
US5492933A (en) 1993-10-08 1996-02-20 Sepracor, Inc. Methods and compositions for treating urinary incontinence and other disorders using optically pure R-terodiline and hydroxylated derivatives thereof
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
SE9701144D0 (sv) 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
JP2004512531A (ja) 2000-10-26 2004-04-22 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 電子デバイス
US6890920B2 (en) * 2001-10-26 2005-05-10 Pharmacia & Upjohn Company Quaternary ammonium compounds
US20040242569A1 (en) * 2003-04-15 2004-12-02 Pfizer Inc. Quatemary ammonium compounds
EP1620389A1 (en) * 2003-04-25 2006-02-01 Pharmacia & Upjohn Company LLC Halogen substituted 3,3-diphenylpropylamines (tolterodine) having antimuscarinic activity

Also Published As

Publication number Publication date
EP1461306A1 (en) 2004-09-29
DK1461306T3 (da) 2009-03-09
ATE418534T1 (de) 2009-01-15
JP3981357B2 (ja) 2007-09-26
CY1109898T1 (el) 2014-09-10
MY130316A (en) 2007-06-29
US6890920B2 (en) 2005-05-10
NO20032938D0 (no) 2003-06-26
CA2464223C (en) 2009-05-26
SG168451A1 (en) 2011-02-28
MXPA04003865A (es) 2004-07-08
WO2003035599A1 (en) 2003-05-01
US20050148672A1 (en) 2005-07-07
EP1461306B1 (en) 2008-12-24
DE60230546D1 (de) 2009-02-05
US7439397B2 (en) 2008-10-21
BR0206207A (pt) 2003-12-23
US20030158176A1 (en) 2003-08-21
CA2464223A1 (en) 2003-05-01
JP2005524605A (ja) 2005-08-18
ES2315425T3 (es) 2009-04-01
PT1461306E (pt) 2009-04-01

Similar Documents

Publication Publication Date Title
NO20032938L (no) Kvatern¶re ammoniumforbindelser samt deres anvendelse som anti-muskariniskemidler
PA8546301A1 (es) Resolucion de sal quiral
BR122012009534C8 (pt) 4-[2-(4-metil-fenil-sulfanil)-fenil]-piperidina, seu uso e composição farmacêutica compreendendo o referido composto
NO20052884D0 (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
DK1651621T3 (da) 2-(Quinoxalin-5-ylsulfonylamino)benzamidforbindelser som CCK2-modulatorer
BRPI0714558B8 (pt) processo para a preparação de (1r,2r)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol
BRPI0411268C8 (pt) Processo para a preparação de compostos 3-aril butil-amina substituído
NO20041339D0 (no) Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler
ATE455752T1 (de) Herstellung von (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpent namin
DK1602660T3 (da) Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
NO20061412L (no) Terapi av okulaere foretyrrelser
SE0702536L (sv) Kvartära ammoniumföreningar med lång kedja som träbehandlingsmedel
EA200701738A1 (ru) Способ получения транс-1-((1r,3s)-6-хлор-3-фенилиндан-1-ил)-3,3-диметилпиперазина
NO20043013L (no) Tetrahydrokinolin analoger som muskarine agonister
DK1960077T3 (da) Kationudvekslings-forskydningskromatografifremgangsmåde og kationiske, organiske forbindelser til anvendelse som forskydningsforbindelser i kationudvekslings-forskydningskromatografifremgangsmåde
BRPI0507847A (pt) processo para a preparação de um composto, e, composto
DE602004014806D1 (de) Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors
DK1210326T3 (da) Hydroxamsyreforbindelser, der er nyttige som matrixmetalloproteinaseinhibitorer
DK1330458T3 (da) N-(1,2,4-triazoloazinyl)thiophensulfonamidforbindelser som herbicider
ITMI20050249A1 (it) Procedimento per la preparazione di tolterodina
BR9915868A (pt) Processo para a decomposição de tramadol
BRPI0412721A (pt) processo para preparar bromidrato de eletriptano alfa-polimórfico
AR051991A1 (es) Procedimiento para la preparacion de anilinas
BRPI0408453A (pt) composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application